Société Mallinckrodt OTC Markets
Actions
MNKKQ
IE00BBGT3753
Produits pharmaceutiques
Métier
Nombre d'employés: 2 786
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Chief Executive Officer | 55 | 25/06/22 | |
Bryan Reasons
DFI | Director of Finance/CFO | 56 | 18/03/19 |
Kassie Harrold
CMP | Compliance Officer | - | - |
Peter Richardson
CTO | Chief Tech/Sci/R&D Officer | 64 | 12/01/23 |
Derek Belz
IRC | Investor Relations Contact | - | 01/04/22 |
Investor Relations Contact | - | 01/01/13 | |
Lisa French
PRN | Corporate Officer/Principal | - | - |
Jason Goodson
PRN | Corporate Officer/Principal | 43 | - |
Mark Tyndall
LAW | General Counsel | - | 01/06/14 |
Corporate Officer/Principal | 47 | - |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Wesley Wheeler
BRD | Director/Board Member | 68 | 02/02 |
Paul Bisaro
CHM | Chairman | 63 | 16/06/22 |
Chief Executive Officer | 55 | 25/06/22 | |
David Stetson
BRD | Director/Board Member | 67 | 14/11 |
Shah Hussain
BRD | Director/Board Member | 59 | 02/02 |
Katina Dorton
BRD | Director/Board Member | 66 | 02/02 |
Jon Zinman
BRD | Director/Board Member | - | 14/11 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 19 696 335 | 19 696 335 ( 100,00 %) | 0 | 100,00 % |
Participations
Nom | Actions | % | Valorisation |
---|---|---|---|
SILENCE THERAPEUTICS PLC 4,70% | 5 062 167 | 4,70% | 4 454 707 $ |
Coordonnées société
Mallinckrodt Plc
College Business & Technology Park Cruiserath
15, Blanchardstown
+353 1 696 0000
http://mallinckrodt.comSociétés du groupe
Nom | Catégorie et Secteur |
---|---|
Sucampo Pharma LLC
Sucampo Pharma LLC Miscellaneous Commercial ServicesCommercial Services Sucampo Pharma LLC engages in the pharmaceutical product development. It develops the naturally occurring compound prostones, including lubiprostone under the brand Amitiza, which is used for the treatment of chronic constipation, chronic idiopathic constipation (CIC) in adults, and irritable bowel syndrome with constipation (IBS-C). The company is headquartered in Osaka, Japan. |
Miscellaneous Commercial Services
|
Sucampo GmbH
Sucampo GmbH Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Sucampo GmbH is a Swiss pharmaceutical company that manufactures and distributes healthcare products. The private company is based in Zug, Switzerland. The company was founded by Ryuji Ueno, Sachiko Kuno. Sucampo was acquired by Sucampo Pharmaceuticals, Inc., part of Mallinckrodt Plc from February 14, 2018 on December 29, 2010 for $120 million. |
Pharmaceuticals: Major
|
Mallinckrodt Group SARL
| |
Mallinckrodt Windsor SARL
Mallinckrodt Windsor SARL Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Windsor SARL provides pharmaceutical products. The private company is based in Luxembourg, Luxembourg. |
Pharmaceuticals: Major
|
Mallinckrodt International Holdings SARL
Mallinckrodt International Holdings SARL Financial ConglomeratesFinance Part of Mallinckrodt Plc, Mallinckrodt International Holdings SARL functions as an investment holding Luxembourger company. The private company is based in Luxembourg, Luxembourg. |
Financial Conglomerates
|
Mallinckrodt Pharmaceuticals Ltd.
Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Pharmaceuticals Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The private company is based in Staines Upon Thames, UK and was founded in 2015. |
Pharmaceuticals: Major
|
Secteur
Varia. 1 janv. | Capi. | |
---|---|---|
+33,46 % | 701 Md | |
+26,24 % | 570 Md | |
+0,93 % | 381 Md | |
+21,03 % | 334 Md | |
+17,51 % | 322 Md | |
+2,95 % | 212 Md | |
+0,74 % | 209 Md | |
-6,05 % | 205 Md | |
-3,61 % | 157 Md |